Literature DB >> 21289264

Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas.

Eleonora Borbone1, Giancarlo Troncone, Angelo Ferraro, Zuzana Jasencakova, Lovorka Stojic, Francesco Esposito, Nadine Hornig, Alfredo Fusco, Valerio Orlando.   

Abstract

CONTEXT: Enhancer of zeste homolog 2 (EZH2) is a histone lysine methyltransferase belonging to the polycomb group protein family. Overexpression of EZH2 has been found in several human malignancies including hematological and solid tumors.
OBJECTIVES: In this study we investigated the expression levels of EZH2 and its polycomb group protein partners in thyroid carcinoma tissues with different degrees of malignancy to identify potential new therapeutic targets for anaplastic thyroid carcinoma (ATC).
RESULTS: We show that high EZH2 expression levels are characteristic of undifferentiated ATC, whereas no significant changes were observed in well-differentiated papillary and follicular thyroid carcinomas as compared with normal thyroid. Knockdown of EZH2 in ATC cell lines results in cell growth inhibition, loss of anchorage-independent growth, migration, and invasion properties. Moreover, we demonstrate that EZH2 directly controls differentiation of ATC cells by silencing the thyroid specific transcription factor paired-box gene 8 (PAX8).
CONCLUSIONS: EZH2 is specifically overexpressed in ATC, and it directly contributes to transcriptional silencing of PAX8 gene and ATC differentiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289264     DOI: 10.1210/jc.2010-1784

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

Review 2.  HMGA1-pseudogene overexpression contributes to cancer progression.

Authors:  Francesco Esposito; Marco De Martino; Floriana Forzati; Alfredo Fusco
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

3.  CircRNA LRP6 promotes the development of osteosarcoma via negatively regulating KLF2 and APC levels.

Authors:  Shengnai Zheng; Zhanyang Qian; Fan Jiang; Dawei Ge; Jian Tang; Hongtao Chen; Jin Yang; Yilun Yao; Junwei Yan; Lei Zhao; Haijun Li; Lei Yang
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

4.  EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.

Authors:  Katsuhiko Masudo; Nobuyasu Suganuma; Hirotaka Nakayama; Takashi Oshima; Yasushi Rino; Hiroyuki Iwasaki; Kenichi Matsuzu; Kiminori Sugino; Koichi Ito; Tetsuo Kondo; Yoshiyasu Nakamura; Mitsuyo Yoshihara; Munetaka Masuda; Yohei Miyagi
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 5.  Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.

Authors:  Neal Smith; Carmelo Nucera
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 6.  Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.

Authors:  Maryam Zarkesh; Azita Zadeh-Vakili; Fereidoun Azizi; Forough Foroughi; Maziar Mohammad Akhavan; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

7.  HMGA1-pseudogene expression is induced in human pituitary tumors.

Authors:  Francesco Esposito; Marco De Martino; Daniela D'Angelo; Paula Mussnich; Gerald Raverot; Marie-Lise Jaffrain-Rea; Filippo Fraggetta; Jacqueline Trouillas; Alfredo Fusco
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  Overexpression of Histone H3 Lysine 27 Trimethylation Is Associated with Aggressiveness and Dedifferentiation of Thyroid Cancer.

Authors:  Chia-Chi Tsai; Ming-Nan Chien; Yuan-Ching Chang; Jie-Jen Lee; Shuen-Han Dai; Shih-Ping Cheng
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

9.  HMGA1 induces EZH2 overexpression in human B-cell lymphomas.

Authors:  Marco De Martino; Pedro Nicolau-Neto; Luis Felipe Ribeiro Pinto; Alexandra Traverse-Glehen; Emmanuel Bachy; Vincenzo Gigantino; Rossella De Cecio; Francesco Bertoni; Paolo Chieffi; Alfredo Fusco; Francesco Esposito
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 10.  Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.

Authors:  Gauri Deb; Vijay S Thakur; Sanjay Gupta
Journal:  Epigenetics       Date:  2013-04-17       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.